Tigecycline, a member of a new class of antimicrobials (glycylcyclines), was shown to have expanded broad spectrum activity against most commonly encountered species responsible for community and hospital acquired infections, including Gram-positive and Gram-negative multidrug resistant bacterial strains. The aim of the study was to evaluate the activity of tigecycline against resistant bacterial strains commonly associated with nosocomial infections, including skin structure, subcutaneous layer and intra-abdominal infections. Material and methods. Ten general hospitals from different regions of Poland participated in the study. Antimicrobial susceptibility tests were carried for 539 isolates of different genus/species of bacterial strains isolated from patients hospitalized in hospitals throughout Poland. Minimal inhibitory concentrations (MICs) of tigecycline were determined using the broth dilution method. Results. Ten strains of 50 S. aureus isolates, i.e. 20%, were methicillin-resistant (MRSA). The lowest MIC 90 values observed for tigecycline were (0.25 µg/ml); they were similar to the MIC 50 for MSSA and MRSA. S. pneumoniae varied with respect to their susceptibility to penicillin. Twenty two percent of isolates (n=11) had decreased susceptibility to penicillin. However, all 50 strains of this species were susceptible to levofloxacin, vancomycin and linezolid. Tigecycline exhibited high activity against S. pneumoniae strains. Tigecycline MIC 90 values for this group of strains were lower than MIC 90 of the remaining antibiotics. One hundred percent of collected S. agalactiae strains were susceptible to all investigated antibiotics. Conclusion. The presented data indicate that tigecycline exhibits excellent inhibitory activity against nosocomial and community pathogens regardless of resistance patterns.
Tigecycline is a new semisynthetic antibiotic, the first drug available in a class of glycylcyclines. It exhibits high activity against a wide spectrum of Gram-positive and Gram-negative microorganisms, both "typical" and "atypical" aerobic and anaerobic organisms. It also exhibits high activity against the most common etiological agents of nosocomial and community infections that exhibit various resistance mechanisms such as methicillin-resistant staphyolcoccus (MRSA), vancomycin-resistant enterococcus (VRE), multi-drug resistant pneumococcus or strains producing extended spectrum b-lactamase (ESBL-positive) (1) .
The aim of this study was to evaluate the activity of tigecycline against resistant bacterial strains commonly associated with nosocomial infections, including skin structure, subcutaneous layer and intra-abdominal infections.
MATERIAL AND METHODS
Ten general hospitals from different regions of Poland participated in this study. Each of 588 E. Stefaniuk, W. Hryniewicz -H. influenzae -ampicillin, amoxicillin with clavulanic acid, ceftriaxone, imipenem, meropenem, ciprofloxacin, levofloxacin; -Enterobacteriaceae: E. coli, Klebsiella spp., Serratia spp. and Enterobacter spp. -amoxicillin with clavulanic acid, ceftriaxone, ceftazidim, cefepim, imipenem, meropenem, ciprofloxacin, levofloxacin, gentamicin, amikacin and netilmicin; -Acinetobacter spp. -ticarcillin with clavulanic acid, ceftriaxone, ceftazidim, cefepim, imipenem, meropenem, ciprofloxacin, levofloxacin, gentamicin, amikacin and netilmicin; -S. maltophilia -ticarcillin with clavulanic acid, ceftriaxone, ceftazidim, cefepim, ciprofloxacin, levofloxacin, gentamicin, amikacin and netilmicin. Drug susceptibility was determined according to recommendations of the Clinical and Laboratory Standards Institute (CLSI, previously NCCLS) using broth microdulutions and determination of the minimal inhibitory concentrations of the pathogens (3). MIC 50 and MIC 90 , were determined, corresponding to drug concentration that inhibits growth of 50% and 90%, respectively, of bacterial strains from an examined collection, based on obtained MIC values (4) . The susceptibility category was interpreted according to CLSI recommendations, except for one case: for S. pneumoniae, susceptibility category for ciprofloxacin was determined according to the French recommendations (5,6). Susceptibility for tigecycline was interpreted according to FDA (Food and Drug Administration) recommendations (www.fda.gov/cder/foi/label/2005).
The following reference strains from ATCC, American Type Culture Collection, were used as quality control: E. coli ATCC 25922, E. coli ATCC 35218, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, S. aureus ATCC 29213, S. aureus ATCC 25923, S. aureus ATCC 43300, S. aureus MR3, E. faecalis ATCC 29212, E. faecalis ATCC 51299, S. pneumoniae ATCC 49619 and from the collection of National Medicines Institute MIKROBANK: E. faecalis 11.001, E. cloacae 10.011, K. pneumoniae 10.021, S. aureus 14.001 (7).
RESULTS
Local laboratories sent 550 bacterial isolates on transportation media to the coordinating laboratory. Eleven clinical isolates that did these hospitals had a microbiology laboratory that participated successfully in the National External Quality Assessment Scheme in Microbiology POLMICRO organized by the Centre of Quality Control in Microbiology in Warsaw (2) .
Each center collected 55 clinical isolates (5 from each genus/species) from the following genus/species: Streptococcus pneumoniae, Streptococcus agalactiae, Staphylococcus areus, Enterococcus spp., Haemophilus influenzae, Escherichia coli, Klebsiella spp., Enterobacter spp., Serratia spp., Acinetobacter spp. and Stenotrophomonas maltophilia. The isolates were collected from June to November 2005 and transported to the coordinating laboratory, the National Medicines Institute (previously National Institut of Public Health). Only isolates from patients over 18 years of age were included in the study. The number of isolates from urine collected by a single laboratory could not exceed 25% of all the bacterial strains collected. Only one isolate of any bacterial species could be collected from a single patient. For each bacterial isolate, the local laboratory attached a completed questionnaire containing demographic and clinical data on the patient from whom the isolate was obtained. Results on the identification and susceptibility to tigecycline and other tested antibiotics of the isolate were also recorded on the questionnaire.
In the local laboratory identification was conducted to the species level according to routine procedures. Bacterial isolates that were sent to the coordinating laboratory were reidentified using standard methods. All isolates qualified for the study were tested for susceptibility to tigecycline and selected antimicrobial drugs, outlined below: -S. aureus -methicillin (Kirby-Bauer disk diffusion methods with cefoxitin 30 µg), gentamicin, amikacin, netilmicin, ciprofloxacin, levofloxacin, vancomycin and linezolid; -S. pneumoniae -penicillin, ceftriaxone, imipenem, meropenem, ciprofloxacin, levofloxacin, vancomycin and linezolid; -S. agalactiae -ampicillin, ceftriaxone, imipenem, meropenem, ciprofloxacin, levofloxacin, vancomycin and linezolid; -Enterococcus spp. -ampicillin, ciprofloxacin, levofloxacin, vancomycin and linezolid, presence of high level aminoglycoside resistance (HLAR) phenotype was determined with disk diffusion method with gentamicin 120 µg and streptomicin 300 µg); not meet the required collection criteria (more then one isolate of the same species from the same patient, patient's age under 18 years) were rejected. Antimicrobial drug susceptibility testing was performed on 50 isolates of each genus/species; except for S. maltophilia, of which only 39 strains were studied. Details of the collected strains that qualified for the study and the clinical speciments that the strains were isolated from, are presented in tab. 1.
The isolates under study were obtained from various clinical specimens: the highest number (n=165) were isolated from skin and subcutaneous tissue infections, including specimens from surgical site infections, lower respiratory tract specimens (BAL, sputum, bronchial discharge) -138 strains, blood -74 strains, upper respiratory tract -31, urine -67, fluids from body cavities -32, vaginal/cervical smears (for S. agalactiae) -12 and other -20. According to prespecified rules, the number of isolates from urine constitutes only a minor portion of collected specimens (n=67, 12%).
Susceptibility to antibiotics
Ten strains from 50 S. aureus isolates, i.e. 20%, were methicillin-resistant (MRSA). The lowest MIC 90 values were observed for tigecycline (0.25 µg/ml); they were the same as MIC 50 and were identical for MSSA and MRSA (tab. 2).
S. pneumoniae varied with respect to their susceptibility to penicillin. Twenty two percent of isolates (n=11) had decreased susceptibility to penicillin. However, all 50 strains of this species were susceptible to levofloxacin, vancomycin and linezolid. Tigecycline exhibited high activity against S. pneumoniae strains. Tigecycline MIC 90 values for this group of strains were lower than the MIC 90 of the remaining antibiotics (tab. 2). One hundred percent of collected S. agalactiae strains were susceptible to all investigated antibiotics.
Among strains from the genus Enterococcus, 52% were found to have a high level of aminoglycoside resistance (HLAR, E. faecalis -15 out of 34 strains, E. faecium -11 out of 16 isolates). Furthermore, marked differences in E. faecalis and E. faecium susceptibility to the remaining drugs was observed, with a higher susceptibility of E. faecalis. Tigecycline exhibited high in vitro activity also in this group, which was reflected by low MIC 50 and MIC 90 values. H. influenzae strains, isolated mainly from lower respiratory tract specimens, exhibited high susceptibility to the investigated antibiotics.
Gram-negative rods from Enterobacteriaceae family (n=200) and non-fermenting rods (n=89), which were mainly isolated from infections of lower respiratory tract, urinary tract, skin and subcutaneous tissue infections, including surgical site infections, constituted a significant group in the study. Fourteen percent of Enterobacteriaceae strains (E. coli -10 isolates; K. pneumoniae -9; K. oxytoca -1, S. marcescens -5 and Enterobacter cloacae -3 isolates) produced extended spectrum b-lactamase (ESBL). E. coli and Klebsiella spp. proved markedly more susceptible to antibiotics compared to Serratia spp. and Enterobacter spp. MIC 50 and MIC 90 values for tigecycline were lower for these strains, to ranging and ranging from 0.12 µg/ml to 2 µg/ml (tab. 2). All ESBL-positive strains were susceptible to tigecycline and only four Enterobacter cloacae had increased MIC for tigecycline = 4 mg/ml. Among all investigated clinical isolates, nonfermenting rods Acinetobacter spp. and S. maltophilia exhibited the highest resistance to antibiotics tested in the study (MIC 90 ³ 256 µg/ml). The percentage of strains susceptible to the majority of drugs was approximately 30%, and to gentamicin only 10.3%. No S. maltophilia isolate was susceptible to ticarcillin with clavulanic acid. Clear multiresistance of S. maltophilia and Acinetobacter spp. (mainly A. baumannii) resulted in low MIC 50 and MIC 90 values for tigecycline (0,5-2 µg/ml) (tab. 2).
DISCUSSION
The increased incidence of infections caused by multidrug-resistant bacterial strains has created a serious threat for patients since the choice of effective antibiotics has become more and more limited. Thus, the search for new effective antimicrobial drugs that would be effective in the treatment of infections caused by multiresistant bacteria has become one of the main medical needs. The launching of tigecycline is welcomed, especially in view of its activity against multi drug resistant bacterial species. In particular, these bacteria include methicillin-resistant Staphylococcus spp. (MRSA), Enterococcus spp. resistant to high aminoglycoside concentrations (HLAR) and resistant to glycopeptides (VRE), Enterobacteriaceae producing extended-spectrum b-lactamase and multiresistant non-fermenting Gram-negative rods. Continuous monitoring of epidemiological situation of infections, i.e. knowledge of etiology and in vitro susceptibility of microorganisms isolated from infections, is necessary for proper therapeutic decisions. In vitro investigations in a significant degree to predict clinical efficacy. Tigecycline has been approved by both FDA and EMEA based on its efficacy demonstrated in randomized clinical studies in patients with skin, subcutaneous tissue and intra-abdominal infections. Postoperative surgical site infection remains still a serious and frequent complications in nearly 3% of all abdominal cavity surgical procedures (8, 9) . Annually, surgical site infections occur in over one million patients in the United States, increasing costs of therapy on average 20% and prolonging an average duration of hospitalization at least seven days (10) . In general surgery, surgical procedures of large intestine complicated with septic conditions and intraabdominal septic complications, require early intervention with proper antibacterial therapy, which currently is very difficult due to widespread multi drug-resistant. These infections are often caused by mixed bacterial flora, and thus launching of tigecycline, characterized by broad-spectrum activity both against anaerobes and aerobes, is a therapeutic advance and offers new opportunity to effectively treat infections caused by multiresistant strains, which are the principle cause of nosocomial infections.
In this study, we showed high in vitro tigecycline activity against the most common etiological agents of surgical site infections. In vitro tigecycline activity was also demonstrated in preclinical studies for aerobic and anaerobic pathogens and confirmed in international clinical studies (11, 12, 13) . For example, tigecycline MIC 90 for methicillin-resistant S. aureus, isolated in multicenter preclinical and clinical studies, was 0.25 µg/ml; similarly, tigecycline MIC 90 for E. coli in both studies was 0.5 mg/ml and MIC 90 = 4 µg/ml for Bacteroides fragilis. Studies of Bradford et al. (1) included clinical isolates from patients from 38 countries of North America, Central America, Eastern Europe, India, South Africa and Australia. Despite the fact that regional trends in susceptibility of respective species to tigecycline was noted, good tigecycline activity against a broad spectrum of pathogens was reported and the majority were inhibited by tigecycline concentrations £ 2 µg/ml. MIC 50 and MIC 90 values for tigecycline for all Gram-positive pathogens (S. aureus, S. pyogenes, E. faecalis and S. anginosus) were almost identical and for pathogens from various regions from all over the world differed with only one dilution; similarly for E. coli, while no differences in MIC 50 and MIC 90 values for tigecycline were observed for K. pneumoniae isolated from patients from distant regions worldwide. Identical trend towards similar MIC 50 and MIC 90 values for tigecycline was observed in this study of Polish isolates, which is very important in view of the fact that no difference was also noted for multiresistant strains, eauipped with such resistance mechanism as ESBL, methicillin-resistance, HLAR and vancomycin-resistance.
New reports are coming, documenting successful attempts of treatment infections with tigecycline, in which other antibiotics failed previously. Among all, they refer to the treatment of invasive MRSA infections (12) or treatment of MRSA pneumonia in a patient after liver transplantation, who previously received linezolid therapy (13) .
Randomized, double blind clinical trials demonstrated good clinical efficacy of tigecycline. Ellis-Grosse et al. compared tigecycline activity as monotherapy in the treatment of skin and subcutaneous tissue infections with activity of combined vancomycin and aztreonam therapy (14) . The demonstrated clinical efficacy was comparable; high clinical efficacy was reflected by low MIC values for isolated pathogens. For the majority of isolates representing Streptococcus pyogenes, S. agalactiae, S. anginosus, E. faecalis (vancomycin-susceptible), E. coli and B. fragilis, the MIC 90 for tigecycline was £ 0.5 µg/ml, and for MSSA, the MIC 90 for tigecycline was 0.25 µg/ml. In vitro studies confirmed results of tigecycline clinical efficacy in vivo against pathogens responsible for skin and subcutaneous tissue infections, including etiological agents of surgical site infections.
On the other hand, Babinchak et al. conducted a randomized double blind clinical trial that examined tigecycline efficacy in intraabdominal infections, which are often of mixed etiology (15) . Etiological agents of these infections included anaerobes: B. fragilis, Clostridium perfringens, Peptostretptococcus micros and aerobes: Enterobacteriaceae, S. aureus (MRSA and MSSA), S. anginosus, E. faecalis (vancomycin-susceptible). E. coli included both ESBL-positive and ESBL-negative strains, but tigecycline activity against this group of isolates was similar to K. pneumoniae. The obtained MIC 90 values for tigecycline were 1-2 µg/ ml for anaerobic flora and 0.25-1 µg/ml for aerobic flora. Only two isolates of K. pneumoniae and Morganella morganii had an MIC of 8 mg/ ml, which according to FDA recommendations means decreased susceptibility. According to FDA recommendations, they should undergo testing in a reference laboratory to confirm the susceptibility phenotype. In our study, we noted a MIC 4 µg/ml, which corresponded to moderate susceptibility, in single isolates of K. pneumoniae, E. cloacae and S. maltophilia.
In this study, a marked number of clinical isolates (n = 243, i.e. 45.1%) were taken from blood and materials from lower and upper respiratory tract infections and had low MIC values for tigecycline. Principle pathogens of lower respiratory tract infections were also examined in vitro by other teams, e.g. Hoban et al. (16) and Betriu et al. (17) . In these studies, the tigecycline MIC 90 for H. influenzae was 0.25 µg/ml and 2 µg/ml, while the S. pneumoniae MIC was 0.25-0.5 µg/ml. In vitro tigecycline activity against bacterial pathogens of the lower respiratory tract is in the process of clinical verification in phase III clinical trials.
CONCLUSION
Tigecycline proved to be a drug of high in vitro activity against a broad spectrum of aerobic Gram-positive and Gram-negative bacterial pathogens responsible for various infections, including skin, subcutaneous tissue infections and surgical site infections, characterized by multiresistance to most antibacterial drugs due to multiple microbial resistence mechanisms.
